-+ 0.00%
-+ 0.00%
-+ 0.00%

Nexentis unit MitoCareX Bio generates optimized hit molecule for cancer, inflammation program

PUBT·05/18/2026 13:30:34
Listen to the news
Nexentis unit MitoCareX Bio generates optimized hit molecule for cancer, inflammation program
  • MitoCareX Bio, a wholly owned subsidiary of Nexentis Technologies, generated an optimized hit molecule with improved pharmaceutical properties versus the program’s initial hit compound, based on parameters assessed as of March 31, 2026.
  • The milestone advances MitoCareX’s small-molecule program targeting a mitochondrial SLC25 carrier protein, aimed at potential treatments for hard-to-treat cancers and inflammatory metabolic diseases.
  • MitoCareX is moving toward pre-clinical trials while continuing medicinal chemistry work to progress to a lead molecule.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180930PRIMZONEFULLFEED9722107) on May 18, 2026, and is solely responsible for the information contained therein.